Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $45.50M
• Dividend Yield: N/A
• Average Volume (3M): 242.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.88
• Revenue Growth: 245.26%
• EPS Growth: 27.54%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -1.49
• Shares Outstanding: 47,899,240
• 10 Day Avg. Volume: 511,439
• 30 Day Avg. Volume: 242,448
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 8.90
• Price to Cash Flow (P/CF): -0.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 321.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

Shattuck Labs shows impressive revenue growth, but persistent challenges in profitability and cash flow create significant risks. The strong balance sheet provides some stability. Technical indicators suggest a bearish trend, and valuation metrics highlight profitability concerns outweighing potential upside. Strategic adjustments are crucial to improve the company's financial health and market perception.

Positive Factors

Innovative Treatment Approach

The pivot into inflammatory bowel disease is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.

Investor Interest

Key Phase 1 milestones for SL-325 are expected to spur investor interest, marking the first clinical data following the company's strategic pivot.

Preclinical Data

Encouraging IND-enabling data for SL-325 indicates a clean safety profile and favorable dosing, which aligns with approved therapies.

Negative Factors

Enterprise Value

The opportunity for value inflection is seen given the company's negative enterprise value and the strategic pivot into a competitive IBD market.

Financial Performance

Shattuck posted a full-year EPS of ($1.49), which was below consensus estimates.

Pipeline Stage

Analyst maintains a Hold Rating given the early stage of the company pipeline at this time and a lack of near-term value drivers.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company focused on developing transformative therapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create novel biologic medicines that have the potential to improve clinical outcomes for patients. Shattuck Labs operates in the biotechnology sector, with a strong emphasis on innovative therapeutic solutions.

How the Company Makes Money

Shattuck Labs generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve the co-development and commercialization of its proprietary ARC platform-based therapies. Additionally, the company may earn revenue from milestone payments and royalties associated with the successful advancement and commercialization of its therapeutic candidates. As a clinical-stage company, Shattuck Labs may also receive funding from grants or research collaborations to support its research and development activities.

Shattuck Labs Financial Statement Overview

Summary

Shattuck Labs shows strong revenue growth but remains unprofitable with significant operational challenges, including negative EBIT and EBITDA. The balance sheet is stable with low leverage, but ongoing losses and negative cash flows necessitate strategic adjustments.

Income Statement

Shattuck Labs has shown significant revenue growth from the previous year, with a Revenue Growth Rate of approximately 245.32%. However, the company remains unprofitable with a negative Net Profit Margin of -131.82% and a negative EBIT Margin. The company has consistently generated negative EBIT and EBITDA over the years, indicating ongoing operational challenges.

Balance Sheet

The balance sheet shows a stable equity position with a Debt-to-Equity Ratio of 0.03, indicating low leverage. The Equity Ratio of 87.47% suggests a strong equity base relative to total assets. However, the company has a history of net losses, which could impact future equity stability.

Cash Flow

Free cash flow remains negative, though there’s a slight improvement in free cash flow growth rate compared to previous years. The Operating Cash Flow to Net Income Ratio is negative, reflecting cash flow issues. The company's cash position has been supported by financing activities, highlighting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
5.72M	1.66M	652.00K	30.02M	9.93M
	Gross Profit
5.72M	-2.38M	-2.72M	28.64M	-27.55M
	EBIT
-80.57M	-91.96M	-103.33M	-45.27M	-36.93M
	EBITDA
-80.57M	-87.61M	-100.26M	-43.89M	-36.31M
	Net Income Common Stockholders
-75.41M	-87.30M	-100.56M	-44.35M	-35.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
57.39M	130.63M	161.28M	268.80M	335.45M
	Total Assets
91.05M	159.56M	205.32M	298.58M	348.99M
	Total Debt
2.51M	4.20M	4.20M	0.00	0.00
	Net Debt
-54.88M	-121.42M	-43.18M	-92.27M	-157.90M
	Total Liabilities
11.42M	14.86M	29.17M	26.80M	39.13M
	Stockholders Equity
79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow		Free Cash Flow
-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
	Operating Cash Flow
-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
	Investing Cash Flow
-8.51M	110.86M	49.44M	-10.44M	-146.32M
	Financing Cash Flow
787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Negative. The current price of 0.95 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.19, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 30.58 is Neutral, neither overbought nor oversold. The STOCH value of 3.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	54 Neutral	$39.62M	1.35	-58.97%	―	36.45%	―
DTIL	48 Neutral	$46.12M	2.32	19.05%	―	40.98%	―
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
KRON	42 Neutral	$47.42M	―	-69.80%	―	56.62%	26.48%
STTK	41 Neutral	$45.50M	―	-67.23%	―	245.26%	27.54%
PEPG	34 Underperform	$36.94M	―	-79.26%	―	―	14.06%
GANX	31 Underperform	$43.90M	―	-204.95%	―	-100.00%	44.28%